تجاوز إلى المحتوى الرئيسي
المنتج التاريخ معلومات السلامة المرفقات
Hemlibra (Emicizumab) 2020-06-21

Hemlibra® (Emicizumab) and it’s known interaction with certain laboratory assays in patients who become infected with the novel corona virus that causes COVID-19

Megamox (Amoxicillin / Clavulanic acid) 2020-05-06

Megamox® 625mg tablets is associated with a typographic error in the units for the weight of the product stated on the aluminum foil.

XELJANZ (tofacitinib) 2020-04-30

XELJANZ (tofacitinib): increased risk of venous thrombo-embolism and increased risk of serious and fatal infections

Curam (Amoxicillin / Clavulanic acid) 2020-03-11

Update on instruction for the preparation of Curam® (Amoxicillin Clavulanic Acid POS - powder for Oral Suspension) bottles

Ecalta (Anidulafungin) 2020-03-11

Ecalta 100mg Powder for Concentrate for Solution for Infusion (Anidulafungin): Solution for Infusion must no longer be frozen

Hydrochlorothiazide 2020-02-10

Hydrochlorothiazide - Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)

Olmepress (Olmesartan) 2020-01-16

Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan).

Kyprolis® ( Carfilzomib) 2019-12-12

Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation

Esbriet® (Pirfenidone) 2019-12-08

Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI)

FEGONA® 2019-11-14

FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception

هل ساعدك محتوى الصفحة للوصول للمطلوب؟
عرض 1 - 10 من 86